Elevated levels of mitochondrial CoQ 10 induce ROS-mediated apoptosis in pancreatic cancer

Reactive oxygen species (ROS) are implicated in triggering cell signalling events and pathways to promote and maintain tumorigenicity. Chemotherapy and radiation can induce ROS to elicit cell death allows for targeting ROS pathways for effective anti-cancer therapeutics. Coenzyme Q is a critical cof...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2021-03, Vol.11 (1), p.5749
Hauptverfasser: Dadali, Tulin, Diers, Anne R, Kazerounian, Shiva, Muthuswamy, Senthil K, Awate, Pallavi, Ng, Ryan, Mogre, Saie, Spencer, Carrie, Krumova, Katerina, Rockwell, Hannah E, McDaniel, Justice, Chen, Emily Y, Gao, Fei, Diedrich, Karl T, Vemulapalli, Vijetha, Rodrigues, Leonardo O, Akmaev, Viatcheslav R, Thapa, Khampaseuth, Hidalgo, Manuel, Bose, Arindam, Vishnudas, Vivek K, Moser, A James, Granger, Elder, Kiebish, Michael A, Gesta, Stephane, Narain, Niven R, Sarangarajan, Rangaprasad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Reactive oxygen species (ROS) are implicated in triggering cell signalling events and pathways to promote and maintain tumorigenicity. Chemotherapy and radiation can induce ROS to elicit cell death allows for targeting ROS pathways for effective anti-cancer therapeutics. Coenzyme Q is a critical cofactor in the electron transport chain with complex biological functions that extend beyond mitochondrial respiration. This study demonstrates that delivery of oxidized Coenzyme Q (ubidecarenone) to increase mitochondrial Q-pool is associated with an increase in ROS generation, effectuating anti-cancer effects in a pancreatic cancer model. Consequent activation of cell death was observed in vitro in pancreatic cancer cells, and both human patient-derived organoids and tumour xenografts. The study is a first to demonstrate the effectiveness of oxidized ubidecarenone in targeting mitochondrial function resulting in an anti-cancer effect. Furthermore, these findings support the clinical development of proprietary formulation, BPM31510, for treatment of cancers with high ROS burden with potential sensitivity to ubidecarenone.
ISSN:2045-2322